NW Bio reports positive top-line results from phase 3 glioblastoma trial
Northwest Biotherapeutics, which is developing DCVax personalized immune therapies for solid tumor cancers, yesterday (November…
November 18, 2022 - 4 minutes
Northwest Biotherapeutics, which is developing DCVax personalized immune therapies for solid tumor cancers, yesterday (November…